Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

BACKGROUND: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for documented IPF, with similar reimbursement criteria with respect to disease characteristics, prescription through a d...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Respir Res
Asıl Yazarlar: Belhassen, Manon, Dalon, Faustine, Nolin, Maëva, Van Ganse, Eric
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2021
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094468/
https://ncbi.nlm.nih.gov/pubmed/33947414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01714-y
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller